Disclosed herein are methods of treating a tumor in a subject, including administering to the subject one or more miRNA nucleic acids or variants (such as mimics or mimetics) thereof with altered expression in the tumor. Also disclosed herein are compositions including one or more miRNA nucleic acids. In some examples, the miRNA nucleic acids are modified miRNAs, for example, and miRNA nucleic acid including one or more modified nucleotides and/or a 5′-end and/or 3′-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid. Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs in a sample from the subject and comparing the expression in the sample from the subject to a control.

The disclosure relates generally to gamma polyglutamated lometrexol compositions, including delivery vehicles such as liposomes containing the gamma polyglutamated lometrexol, and methods of making and using the gamma polyglutamated lometrexol compositions to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., inflammation and autoimmune diseases such as rheumatoid arthritis).

A rapamycin (RAPA) composition and a preparation method thereof are provided. The RAPA composition includes the following active ingredients in parts by weight: RAPA: 1 to 10 parts; polymer carrier: 0.5 to 20 parts; and lymphatic target: 0.1 to 1 part. The lymphatic target is at least one selected from the group consisting of sodium hyaluronate (SH), an aptamer, and an antibody. The preparation method includes: preparing an organic phase solution by adding RAPA to an organic phase solvent to obtain the organic phase solution; preparing an emulsion by adding a polymer carrier to an aqueous phase solvent and adding the organic phase solution dropwise to the aqueous phase solvent to obtain the emulsion; and conducting homogenization by adding a lymphatic target to the emulsion, mixing, and homogenizing to obtain the RAPA composition. The RAPA composition can target a lymphatic system to treat atherosclerosis (AS) and related cardiovascular diseases (CVDs).

Described herein are liposomes that can be capable of targeting within blood vessels to an intended tissue area presenting at least one vascular inflammatory marker and enhancing imaging contrast therein. Described herein are aspects of a targeting liposome that can carry antibodies against at least one vascular inflammatory marker and a contrast agent to an intended tissue area presenting the at least one vascular inflammatory marker whereby the liposomes can be capable of anchoring to the intended vascular inflammation site and enhancing imaging contrast of it. Also described herein are methods of using the targeting liposomes for anchoring the liposomes to vascular inflammation and imaging vascular inflammation.

Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.

A device for recovering a population of extracellular vesicles from a biological sample comprising extracellular vesicles and contaminants is described.

The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with the polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using the polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Cancer treatment methods using thermotherapy and/or enhanced immunotherapy are disclosed herein. In one embodiment, the method comprising the steps of administering a plurality of nanoparticles to target a tumor in a patient, the nanoparticles being coated with an antitumor antibody, cell penetrating peptides (CPPs), and a polymer, and the nanoparticles containing medication and/or gene, and a dye or indicator in the polymer coating, at least some of the nanoparticles attaching to surface antigens of tumor cells so as to form a tumor cell/nanoparticle complex; exciting the nanoparticles using an ultrasound source generating an ultrasonic wave so as to peel off the polymer coating of the nanoparticles, thereby releasing the dye or indicator into the circulation of the patient and the medication and/or gene at the tumor site; and imaging a body region of the patient so as to detect the dye or indicator released into the circulation of the patient.

The disclosure provides compositions and methods for delivering a payload to cells or tissues that express GLUT4. In some embodiments, the compositions comprise an antibody, or fragment or derivative thereof, that specifically binds to glucose transporter 4 (“GLUT4”) protein, and a therapeutic payload conjugated thereto. In some exemplary embodiments, the compositions are useful for methods of treating a disease or condition in a subject with a genetic mutation in a gene encoding dystrophin protein, wherein the payload comprises a nucleic acid encoding a functional dystrophin protein or functional fragment thereof to ameliorate aspects of the disease.

Ultra-low crosslinked microgels made of an ultra-low crosslinked polymer are provided. The microgels, also referred to as Platelet-like Particles (PLPs), preferably have <0.5% crosslinking densities. One or more of the polymers are conjugated with a fibrin-binding element or moiety, preferably H6, in an amount effective to confer to the microgel selective binding to fibrin under physiological conditions. The PLPs can recapitulate multiple key functions of platelets including binding, stabilizing and enhancing fibrin clot formation, responsiveness to injury cues, and induction of clot contraction. In a preferred embodiment, the microgel or PLP has little or no binding to soluble fibrinogen under physiological conditions compared to its binding to fibrin. The microgels or PLPs are prepared using crosslinker-free synthesis conditions, and can promote or induce clotting and clot contraction.